Inovio Pharmaceuticals (INO) Assets (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Assets of $49.8 million for Q1 2026, down 33.01% sequentially from $74.3 million in Q4 2025, and down 42.96% YoY from $87.3 million in Q1 2025.
Inovio Pharmaceuticals (INO) Assets (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Assets for 17 years, with the latest figure at $49.8 million in Q1 2026.
- Quarterly Assets fell 42.96% year-over-year to $49.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.8 million (down 42.96% YoY) and the FY2025 annual result came in at $74.3 million, down 34.35% from the prior year.
- Assets slipped to $49.8 million in Q1 2026 per INO's latest filing, from $74.3 million in the prior quarter.
- Over five years, Assets peaked at $459.4 million in Q2 2022 and troughed at $49.8 million in Q1 2026.
- A 5-year average of $196.5 million and a median of $133.8 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2024: Assets retreated 22.38% in 2022, then slumped 51.57% in 2024.
- Over 5 years, Assets stood at $348.5 million in 2022, then slumped by 50.95% to $171.0 million in 2023, then tumbled by 33.78% to $113.2 million in 2024, then tumbled by 34.35% to $74.3 million in 2025, then plunged by 33.01% to $49.8 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $49.8 million, $74.3 million, and $69.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | 49.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.39 Mn |
| Mar 31, 2026 | 49.78 Mn |
| Dec 31, 2025 | 74.31 Mn |
| Sep 30, 2025 | 69.39 Mn |
| Jun 30, 2025 | 68.24 Mn |
| Mar 31, 2025 | 87.27 Mn |
| Dec 31, 2024 | 113.20 Mn |
| Sep 30, 2024 | 107.06 Mn |
| Jun 30, 2024 | 133.80 Mn |
| Mar 31, 2024 | 129.11 Mn |
| Dec 31, 2023 | 170.95 Mn |
| Sep 30, 2023 | 193.10 Mn |
| Jun 30, 2023 | 233.04 Mn |
| Mar 31, 2023 | 266.58 Mn |
| Dec 31, 2022 | 348.53 Mn |
| Sep 30, 2022 | 391.97 Mn |
| Jun 30, 2022 | 459.40 Mn |
| Mar 31, 2022 | 445.51 Mn |
| Dec 31, 2021 | 495.94 Mn |
| Sep 30, 2021 | 535.76 Mn |